Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 384 participants.

Also called NCT03359837

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 384 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03359837
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03359837. Randomized; no masking; primary purpose treatment. Start 2018-01-20 (actual); primary completion 2020-06-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
Acronym
SWITCH
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
INSULIN GLARGINE (HOE901)
Intervention (Drug)
Insulin Glulisine
Intervention (Drug)
Biphasic insulin aspart 30
Intervention (Drug)
Repaglinide
Intervention (Drug)
Acarbose
Intervention (Drug)
Metformin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03359837
Content hash
53583fafb436d9b8380bb3729d30f2395e5aa69f5a2d321fe6bbbbb584115269